Rubicon Research Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹120(24.74%)
Premium (ELP)
Following its successful public offering, Rubicon Research Limited's made its market debut on Oct 16, 2025 and is now actively traded on the NSE, BSEplatform. The IPO mobilized 2,84,02,040 Shares in total capital, including 1,03,09,278 Shares in primary equity infusion and ₹877.50 Cr in secondary share sales.
The offering was structured with a price band of ₹461 to ₹485 and minimum investment lots of 30 shares. Investor participation during the subscription window from Oct 09, 2025 to Oct 13, 2025 demonstrated market confidence in the company's prospects.
The allotment process concluded on Oct 14, 2025, allocating shares to successful bidders. The listing represents the culmination of the IPO process, transitioning the company to publicly traded status with enhanced transparency and governance standards.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Rubicon Research Limited, incorporated in 1999, is a pharmaceutical company focused on developing, manufacturing, and commercializing differentiated formulations. As of June 30, 2025, it has 72 US FDA-approved ANDA and NDA products, with 66 commercialized in a US generic market worth USD 2,455.7 million, contributing USD 195 million in Fiscal 2024. The company has 17 products awaiting US FDA approval and 63 in development, marketing over 350 SKUs to 96 customers, including major wholesalers, pharmacy chains, GPOs, and managed care organizations. Globally, Rubicon has registered or filed 48 products across Australia, the UK, Singapore, Saudi Arabia, and the UAE, planning commercial launch upon approval, and offers contract manufacturing in India, Australia, and New Zealand. Its operations include three manufacturing facilities in India and two US FDA-inspected R&D centers in India and Canada.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Robust Product Portfolio: Data-driven selection creates a balanced mix of new and specialty products, helping manage pricing pressures.
- Strong R&D Capabilities: Continuous investment in research enables development of complex, high-revenue products.
- Proven Compliance & Quality Manufacturing: Maintains regulatory standards with cost-effective production and strong quality systems.
- Regulatory & Compliance Risks: Strict manufacturing rules may cause recalls, failed inspections, or plant closures, affecting sales and new launches.
- Financial Performance Risks: Past losses mean profitability depends on growing revenue and managing costs.
- High Capital Requirements: Large working capital and investments are needed; funding issues could disrupt operations.
- Pratibha Pilgaonkar
- Sudhir Dhirendra Pilgaonkar
- Parag Suganchand Sancheti
- Surabhi Parag Sancheti
- Sumant Sudhir Pilgaonkar
Rubicon Research Limited
Link Intime India Private Ltd (MUFG)